关于“隐匿性HBV感染”定义的拙见

薛荣荣; 王欣茹; 肖丽; 刘成元; 王蔚; 徐洪涛; 咸建春

doi:10.3969/j.issn.1001-5256.2023.05.006

关于“隐匿性HBV感染”定义的拙见

DOI: 10.3969/j.issn.1001-5256.2023.05.006

1.
江苏省盐城市第一人民医院感染性疾病科，江苏盐城 224005
2.
江苏省泰州市人民医院感染暨肝病科，江苏泰州 225300

基金项目:

泰州市科技支撑计划(社会发展)项目 (TS201813)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：薛荣荣、王欣茹负责初稿撰写与文献检索；肖丽、刘成元、王蔚参与了科学讨论和部分内容书写；徐洪涛、咸建春拟定写作思路，指导、修改论文，核对有关文献并最后定稿。薛荣荣、王欣茹对本文贡献等同，同为第一作者。

详细信息

通信作者:
咸建春，xianjc09@163.com(ORCID: 0000-0003-0159-2784)

计量
- 文章访问数: 470
- HTML全文浏览量: 72
- PDF下载量: 129
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-16
- 录用日期: 2023-01-05
- 出版日期: 2023-05-20

Opinion on the definition of "occult hepatitis B virus infection"

1.
Department of Infectious Diseases, the First People's Hospital of Yancheng, Yancheng, Jiangsu 224005, China
2.
Department of Infectious Diseases and Hepatology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, China

Research funding:

Taizhou Science and Technology Support Program (Social Development) Project (TS201813)

More Information

Corresponding author: XIAN Jianchun, xianjc09@163.com(ORCID: 0000-0003-0159-2784)

摘要

摘要: 隐匿性HBV感染(OBI)诊断的充分必要条件是指HBsAg阴性个体的肝脏和/或血清中存在具有复制能力的HBV DNA。我国学者近年来对其提出认为是更“严谨”的定义：即在此基础上，排除HBV窗口期(WP)感染，对应血清HBV DNA低于检测下限或低值阳性(＜200 IU/mL)。因HBV感染WP的定义尚不明确、持续时间的高度可变性，而“HBV DNA＜200 IU/mL”不是OBI患者的全部。故认为以“排除HBV感染WP”与“HBV DNA＜200 IU/mL”为诊断OBI“严谨”条件的OBI定义还缺乏充分的依据与可操作性。
- 乙型肝炎病毒 /
- 乙型肝炎 /
- 病毒载量
Abstract: The presence of replication-competent HBV DNA in the liver and/or serum of HBsAg-negative individuals is a sufficient and necessary condition for the diagnosis of occult hepatitis B virus infection (OBI). In recent years, Chinese scholars have proposed what is considered a more "rigorous" definition, i.e., on this basis, HBV window period (WP) infection is excluded, which corresponds to a serum HBV DNA level of below the lower limit of detection or a low positive value (< 200 IU/mL). As the definition of WP for HBV infection remains unclear and its duration is highly variable, "HBV DNA < 200 IU/mL" is not the only criterion in OBI patients. Therefore, it is believed that there is still a lack of sufficient basis and operability for the definition of OBI based on "the exclusion of HBV WP infection" and "HBV DNA < 200 IU/mL" as "rigorous" conditions for the diagnosis of OBI.
- Hepatitis B virus /
- Hepatitis B /
- Viral Load

HTML全文

参考文献(21)

[1]	WANDS JR, CHURA CM, ROLL FJ, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders[J]. Gastroenterology, 1975, 68(1): 105-112. DOI: 10.1007/BF02604283.
[2]	HOOFNAGLE JH, SEEFF LB, BALES ZB, et al. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen[J]. N Engl J Med, 1978, 298(25): 1379-1383. DOI: 10.1056/NEJM197806222982502.
[3]	SAITTA C, POLLICINO T, RAIMONDO G. Occult hepatitis B virus infection: An update[J]. Viruses, 2022, 14(7): 1504. DOI: 10.3390/v14071504.
[4]	RAIMONDO G, ALLAIN JP, BRUNETTO MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection[J]. J Hepatol, 2008, 49(4): 652-657. DOI: 10.1016/j.jhep.2008.07.014.
[5]	RAIMONDO G, LOCARNINI S, POLLICINO T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection[J]. J Hepatol, 2019, 71(2): 397-408. DOI: 10.1016/j.jhep.2019.03.034.
[6]	LU FM, WANG J, CHEN XM, et al. Application of the new serum markers in the research and development of innovative hepatitis B drugs[J]. Chin J Hepatol, 2020, 28(8): 649-653. DOI: 10.3760/cma.j.cn501113-20200722-00410. 鲁凤民, 王杰, 陈香梅, 等. 新型血清指标在乙型肝炎创新药物研发中的应用[J]. 中华肝脏病杂志, 2020, 28(8): 649-653. DOI: 10.3760/cma.j.cn501113-20200722-00410-1.
[7]	WANG J, YU GX, LU FM. Clinical application and significance of highly sensitive HBV DNA detection[J]. J Mol Diagn Ther, 2019, 11(5): 343-347, 373. DOI: 10.3969/j.issn.1674-6929.2019.05.002. 王杰, 于广鑫, 鲁凤民. 高灵敏度HBV DNA检测的临床应用及意义[J]. 分子诊断与治疗杂志, 2019, 11(5): 343-347, 373. DOI: 10.3969/j.issn.1674-6929.2019.05.002.
[8]	ZOU J, WANG J, WANG LN, et al. Research progress on occult hepatitis B virus infection and related blood transfusion safety issues[J]. Chin J Infect Dis, 2020, 38(6): 385-388. DOI: 10.3760/cma.j.cn311365-20191016-00335. 邹军, 王杰, 王露楠, 等. 隐匿性乙型肝炎病毒感染及相关输血安全问题的研究进展[J]. 中华传染病杂志, 2020, 38(6): 385-388. DOI: 10.3760/cma.j.cn311365-20191016-00335.
[9]	LU FM, LIAO H, LIU YZ, et al. Re-recognition of occult hepatitis B virus infection[J]. Chin J Prev Med, 2019, 53(5): 445-449. DOI: 10.3760/cma.j.issn.0253-9624.2019.05.002. 鲁凤民, 廖昊, 刘永振, 等. 隐匿性乙型肝炎病毒感染再认识[J]. 中华预防医学杂志, 2019, 53(5): 445-449. DOI: 10.3760/cma.j.issn.0253-9624.2019.05.002.
[10]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[11]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[12]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[13]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[14]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[15]	World Health Organization. WHO guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2015.
[16]	WU D, WANG X, FENG F, et al. Characteristic of HBV nucleic acid amplification testing yields from blood donors in China[J]. BMC Infect Dis, 2021, 21(1): 714. DOI: 10.1186/s12879-021-06468-y.
[17]	SOLDAN K, RAMSAY M, COLLINS M. Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database[J]. BMJ, 1999, 318(7176): 95. DOI: 10.1136/bmj.318.7176.95.
[18]	MIMMS LT, MOSLEY JW, HOLLINGER FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection[J]. BMJ, 1993, 307(6912): 1095-1097. DOI: 10.1136/bmj.307.6912.1095.
[19]	KLEINMAN SH, BUSCH MP. Assessing the impact of HBV NAT on window period reduction and residual risk[J]. J Clin Virol, 2006, 36(Suppl 1): S23-29. DOI: 10.1016/s1386-6532(06)80005-3.
[20]	TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. DOI: 10.1002/hep.28156.
[21]	IM YR, JAGDISH R, LEITH D, et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(10): 932-942. DOI: 10.1016/S2468-1253(22)00201-1.